🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Over the next 2 weeks hope to do some quick #video summaries of our #Top10Tips paper for #hpm on #survonc. Hope you enjoy! #pallonc #supponc This is Tip 1⃣ cross team collab 🤝 Gregg Robbins-Welty, MD, MS, HEC-C Larissa Nekhlyudov Nicolas Hart Samina B. Martin, MD Billy Rosa, PhD, MBE, APRN OncoAlert🚨 ASCO PallOnc Community of Practice

That feeling when 7+ years of work lands on the front page of NEJM—and one of the people I respect most, Kohei shitara , writes the editorial. Honored to share this moment with you, Kohei. Here’s to a decade of friendship, and curing gastric cancer. #Matterhorn Memorial Sloan Kettering Cancer Center

🌟 Kimryn Rathmell shares her story and inspires action to fight brain drain 🧠💨: empower early careers 🚀, mentor to create opportunity 🤝, and ensure institutions 🏛️ bring young voices to the table while valuing mentors fully 🌱✨ KidneyCAN #kcrs25

🔥Off the press: ASCO #LivingGuidelines for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2025.1 | 👉🏽 ascopubs.org/doi/10.1200/JC… ✅ Clear algorithm for first and second line options ✅ Review of recent data:

Kick-off call for my ⁦ASCO⁩ Virtual Mentorship Program #VMP 2025-26 class | it will be a fun journey with 5 mentees 🇹🇷🇲🇽🇺🇸 ⁦İmdat Eroğlu⁩ ⁦Rafael Correa Cano⁩ ⁦Jordan Ciuro, MD⁩ #SuleymanKarakeçi #HalilİbrahimEllez | ⁦Brigida Maiorano⁩ dropbox.com/scl/fi/mkfssgr…

💡 Great review of progress over the last 10 years in 1st-line metastatic RCC 🚀 and a call from David McDermott to work together to cure more patients with kidney cancer 🤝 KidneyCAN #KCRS25 #rcc #kidneycancer

One of the reasons I love KidneyCAN's #KCRS25: Hearing luminaries in the field of #kidneycancer present their take on data hot off the press. So cool to see Toni Choueiri, MD Robert Motzer MD Naomi Haas #McDermott sharing a stage & offering perspective on the latest from ASCO, ESMO - Eur. Oncology &

Celebrating the winners of the KCRS25 Merit Awards for Clinical Research! 👏 Dr. Yu-wei Chen, University of California San Diego 👏 Dr. Koral Shah, City of Hope 👏 Ruchi Agarwal, University of Pennsylvania #KCRS25 #AcceleratingCures

A force of nature, a catalyst for change and an incomparable energy ! Congrats Rana McKay, MD, FASCO UC San Diego Health Moores Cancer Center ! KidneyCAN #KCRS2025

🚨 MET in Cancer: Mutation, Amplification & Resistance 🧬 MET is a key oncogenic driver—especially in NSCLC, HCC, gastric & RCC. But resistance is smart. It strikes via: 1️⃣ On-target MET mutations (e.g., D1228N, Y1230C/S/H) 2️⃣ Downstream rewiring (KRAS, BRAF, PI3K, PTEN, MYC) 3️⃣

At the heart of science. Not just the data, but how it reaches patients, this is what truly matters. Great discussion on global disparities. Congrats Ruchi Agarwal Sumanta K. Pal, MD, FASCO #KCRS25 #KidneyCancer OncoAlert KidneyCAN UroToday.com City of Hope Neeraj Agarwal, MD, FASCO

It feels truly surreal to be entering this hematology-oncology fellowship application cycle, pursuing my passion for GIOncology. My interests focus on GI cancers, early-onset malignancies, and healthcare disparities, with a special focus on clinical trials. Grateful to all my

At NOSCM, Julia Rotow MD presents provocative data supporting continuation of EGFR TKIs after progressive disease, so-called treatment beyond progression (TBP). I am increasingly a believer. Invariably there are residual sensitive clones which need to be controlled

Fantastic to interview my colleague Dr. John Gore UW Urology Fred Hutch Cancer Center on CISTO study that he presented Amer. Urol. Assn. patient centered & pragmatic study helped answer key questions with interesting results! Sarah P. Psutka MD MS 𝐂𝐡𝐚𝐧𝐝𝐥𝐞𝐫 𝐏𝐚𝐫𝐤 𝐌𝐃 𝐅𝐀𝐂𝐏 OncoDaily Daniel Lin youtu.be/s4IJA1KaoUI

Received a Texas sized farewell from my MD Anderson Cancer Center family, complete with an exceptional brisket from top chef Eugene J. Koay, MD, PhD. Thanks to Stacy & Eugene for hosting and the gang for 12 AMAZING years of friendship & collaboration (both keep going!) Grateful to all of you 🙏🏽🙏🏽

In high-risk prostate cancer, radiotherapy plus ADT significantly reduces the risk of distant metastasis compared to surgery-based approaches. However, post-metastasis survival does not differ between treatments. European Urology Oncology Daniel E Spratt OncoAlert Advanced Prostate Cancer Consensus Conference European Association of Urology (EAU)

our #lungcancer session at MECC New Orleans 2025 with David Gandara IASLC Karen Kelly Eric K. Singhi, MD Julia Rotow MD Paul Bunn Subramanian Fred R. Hirsch Edgardo S. Santos, M.D., FACP, FASCO Megan Daly Erminia Mazarelli #lcsm The Medical Educator Consortium

🚨 FDA grants Priority Review to Johnson & Johnson’s TAR-200, a novel intravesical gemcitabine delivery system for BCG-unresponsive high-risk NMIBC (CIS ± papillary tumors). 📊 In SunRISe-1, TAR-200 showed 82.4% CR and >50% cancer-free at 1 year. #BladderCancer #Immunotherapy

🚨 Big news in #lungcancer! 📢 Final OS data from FLAURA2 💊 Tagrisso + chemo ⬆️ overall survival in 1L EGFRm NSCLC vs Tagrisso alone 🔑 Statistically & clinically meaningful 🧬 Longest median PFS in class 🛡 No restriction on post-progression Rx . It will be intresting to see

Magnitude of OS benefit for FLAURA2 will be relevant here. Since crossover was not mandated per study design, the next question should be what did the control arm receive and when? IMO - the central clinical, real world, question that FLAURA2 is trying to answer is whether